Moderna Inc (#MRNA) Stock Price, Live Chart & Analysis | Trade #MRNA

Interesting facts about the #MRNA (Moderna Inc)

Moderna Inc. was listed for trading on the NASDAQ on December 7, 2018. The initial price was $23.00 per share. An all-time high of $497 was recorded in August 2021. Moderna Inc. shares are traded under the ticker symbol #MRNA. The company does not pay dividends. In July 2021, Moderna joined the S&P 500 index.

As for the company's performance, the US Food and Drug Administration has granted priority consideration to the application for a license for biological preparations for the Moderna COVID-19 vaccine. Moderna reported its third-quarter fiscal year 2021 financial results on November 4, 2021. The total revenue made up $5.0 billion; net income was $3.3 billion and diluted EPS - $7.70. Moderna stock prices are experiencing a downtrend after the company lowered its sales forecast for the vaccine and missed expectations for profit and revenue.

Currently, a number of vaccines are being developed in China and Russia, as well as by other non-Western companies. In this regard, Moderna and BioNTech/Pfizer's shares in the global vaccine market and their ability to charge a high price will continue to decline. Moderna's financial results and forecasts show that, despite the company being extremely profitable, its ability to make money on vaccines is already declining. Since August 2021, there has been a serious correction in the price of the company's securities, from $450 to almost $140, caused by the competition on the global market.

Although Moderna is a young company, it is planning a long-term impact. The field of drug development using an RNA messenger seems to be quite promising. So, looking into the pipeline of the company, there's a large number of new molecules at various stages of preclinical and clinical trials. Moreover, Moderna is demonstrating a commitment to corporate citizenship by creating energy-efficient and sustainable production sites.

On February 17, 2022, the biotech company announced plans to create four subsidiaries in Singapore, Malaysia, Hong Kong, and Taiwan to supply their vaccines to East and Southeast Asia. Moderna is intended to grow and expand its influence worldwide.